Study of Efficacy and Safety of Secukinumab Compared to Ustekinumab in Subjects with Plaque Psoriasis

What we are studying

This is a multicenter, randomized, double-blind, active-controlled, parallelgroup trial in approximately 1100 subjects with moderate to severe chronic plaque-type psoriasis. It is expected that subjects will be enrolled at approximately 200-250 study sites worldwide. The study consists of 3 epochs: screening (of at least 2 weeks and up to 4 weeks), treatment epoch (of 52 weeks: from randomization to Week 52), and follow-up epoch (of 8 weeks: visits F4 and F8 to be conducted at 8 and 12 weeks after last study treatment, for subject with premature treatment discontinuation only.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
  • Not Hispanic or Latino
  • Ages 18+

Eligibility Criteria

  • Chronic plaque-type psoriasis present for at least 6 months before randomization
  • PASI score greater than or equal to 12
  • Body Surface Area (BSA) affected by plaque-type psoriasis greater than or equal to 10%
  • IGA mod 2011 greater than or equal to 3 (based on a scale of 0–4)

What is involved

  • 4 Physical Exams
  • 10 Height/Weight/Vitals
  • 1 TB test
  • 2 Urine Pregnancy Tests
  • 1 ECG
  • 5 Blood Draws

Compensation

$50 Per Completed Visit for a Total of $500

Contact Information

Study Coordinator
Dermatology Clinical Studies
Email
dermadvertising@wakehealth.edu
Phone
336-716-3775
Principal Investigator
Steve Feldman, MD, PhD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.